| Biomarker ID | 384 |
| PMID | 18948370 |
| Year | 2008 |
| Biomarker | Serum PSA + DRE + TMPRSS:ERG |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Expressed Prostatic Secretion |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | OR = 4.239 (95% CI: 1.858–11.870) |
| Effect on Pathways | Pathways Include(ERG):-Genes targeted by miRNAs in adipocytes WP1992,VEGFA-VEGFR2 Signaling Pathway WP3888 |
| Experiment | Benign vs. PCA |
| Type of Biomarker | Diagnostic |
| Cohort | 86 patients were taken into consideration for the test. There were 39 Benign tumors, PCA was detected in 35 patients, and 12 were diagnosed with HGPIN which were excluded from this study. |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.823 (95% CI: 0.728–0.919) |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | methylation-sensitive TaqMan QPCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | TMPRSS2, ERG |